Loxo Links And Colorectal Cancer Data Put Array In M&A Spotlight

Following Lilly's proposed acquisition of Loxo, other possible takeover targets in the precision medicine field have emerged and Array, armed with more positive data on its colorectal cancer triplet, is near the top of the list.

GreenFigure
Array at head of potential M&A target pack • Source: Shutterstock

The chances of Array Biopharma Inc. becoming the next M&A target for big pharma may have increased with more positive data from a late-stage trial of a triplet combination of its BRAF inhibitor Braftovi (encorafenib), MEK inhibitor Mektovi (binimetinib) and Eli Lilly & Co./

Merck KGAA's anti-EGFR antibody Erbitux (cetuximab) for colorectal cancer.

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Deals

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.